Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have fundamentally reshaped the treatment paradigms for type 2 diabetes (T2D) and obesity over the past two decades. Their remarkable success in these cardiometabolic conditions has, however, unveiled a much broader spectrum of physiological activities. Emerging evidence strongly suggests that GLP-1RAs exert pleiotropic effects, holding therapeutic potential across a surprisingly diverse range of diseases far beyond their initial indications. This realization has ignited a new wave of research, positioning GLP-1RAs at the forefront of therapeutic discovery in 2025. This section will explore these cutting-edge research frontiers, focusing on recent (2024-2025) clinical trial data and evolving mechanistic insights into their action in neurodegenerative disorders, chronic kidney disease, cardiovascular disease, and metabolic liver disease.
The potential for GLP-1RAs to address neurodegenerative diseases like Alzheimer’s disease (AD) and Parkinson’s disease (PD) represents one of the most exciting and actively investigated new frontiers.
The rationale for exploring GLP-1RAs in AD stems from several observations: the established epidemiological link between T2D, insulin resistance, and an increased risk of AD; the expression of GLP-1 receptors in key brain regions involved in cognition and memory; and preclinical data suggesting multiple neuroprotective mechanisms.
Mechanisms of Action in AD:
The proposed neuroprotective actions of GLP-1RAs in AD are multifaceted. They are thought to improve brain insulin sensitivity and glucose metabolism, which are often impaired in AD. Anti-inflammatory and antioxidant effects within the central nervous system may also contribute to their benefits. While preclinical studies suggested GLP-1RAs could reduce amyloid-β (Aβ) deposition and tau hyperphosphorylation—hallmark pathologies of AD—human biomarker data from clinical trials have been less consistent in demonstrating these direct effects on core AD pathology. More consistently observed are effects on preserving brain structure and connectivity, enhancing synaptic plasticity, and promoting neurogenesis. An emerging area of interest is the modulation of the gut-brain axis, with some GLP-1RAs like semaglutide potentially influencing gut microbiota composition, which in turn could alleviate neuroinflammation.
Recent Clinical Trial Highlights (2024-2025):
The ELAD Phase 2b trial, reported at the Alzheimer’s Association International Conference (AAIC) in 2024, investigated liraglutide in patients with mild AD. While the trial did not meet its primary endpoint related to changes in cerebral glucose metabolic rate, it demonstrated statistically significant benefits on important secondary and exploratory endpoints. Patients treated with liraglutide showed a slower loss of brain volume in critical areas for memory and cognition (nearly 50% less volume loss in frontal, temporal, parietal, and total gray matter compared to placebo) and experienced an 18% slower decline in cognitive function over one year.
A comprehensive review published in the Journal of Alzheimer’s Disease Reports in May 2025 synthesized findings from ten studies, including randomized controlled trials and observational studies. It concluded that GLP-1RAs consistently demonstrated cognitive benefits in patients with T2D. In individuals with early dementia or AD, GLP-1RA treatment appeared to preserve brain metabolism and connectivity, although significant alterations in amyloid or tau biomarkers were not consistently observed. Notably, cognitive improvements were most evident in individuals with a higher body mass index (BMI) or obesity.
The exploration of GLP-1RAs in PD is driven by similar neuroprotective hypotheses as in AD, including the presence of GLP-1Rs in brain regions affected by PD and the potential for these agents to mitigate neuroinflammation, improve insulin signaling, and provide neurotrophic support.
The PD field has seen both encouraging and cautionary results. The LixiPark Phase 2 clinical trial, with full results published in 2024, found that lixisenatide met its primary endpoint, indicating a slowing in the progression of motor symptoms associated with PD in the treatment group compared to placebo. This positive signal from a Phase 2 study has generated considerable optimism.
However, the Exenatide-PD3 trial, a large-scale Phase 3 clinical trial evaluating exenatide in PD, concluded in early 2024 without meeting its primary endpoint. The trial found no significant benefit of exenatide over placebo in slowing Parkinson’s progression, with full results anticipated in early 2025. A report in The Lancet in February 2025, titled “First phase 3 trial of GLP-1 receptor agonist for neurodegeneration”, likely refers to the Exenatide-PD3 trial, framing its outcome as a key learning point for the field.
Beyond AD and PD, GLP-1RAs are being investigated for broader neuroprotective roles, including in vascular dementia. Proposed mechanisms include the attenuation of hypoperfusion-induced neuronal damage, suppression of oxidative stress and neuroinflammation, reduction of apoptosis, and limiting infarct volume in ischemic conditions. A viewpoint article in JAMA Neurology in April 2025 highlighted the emerging neuroprotective potential of GLP-1RAs, signaling growing interest in this area.
The landscape of GLP-1RAs in neurodegeneration is dynamic and complex. Positive Phase 2 results for lixisenatide in PD and liraglutide in AD provide encouragement. However, the negative outcome of the large Phase 3 Exenatide-PD3 trial serves as a crucial reminder of the challenges in translating promising early findings into definitive clinical benefits. This discrepancy suggests that factors such as the specific GLP-1RA used (as their ability to cross the blood-brain barrier and their receptor interaction profiles may differ), patient selection criteria, disease stage at intervention, and trial design nuances are critically important. Further Phase 3 trials, potentially including head-to-head comparisons or focusing on GLP-1RAs with optimized CNS penetration and neuroprotective mechanisms, are eagerly awaited. The development of oral formulations that can more readily access the brain is also a key area of future research.
The application of GLP-1RAs in the management of chronic kidney disease, particularly in patients with T2D, has marked a significant advancement in nephrology.
Rationale and Mechanisms of Action:
CKD is a common and severe complication of T2D, and there is a substantial unmet need for therapies that can slow its progression. GLP-1RAs have demonstrated renal protective effects that appear to extend beyond their benefits on glycemic control. The proposed mechanisms include:
The FLOW (Evaluate Renal Function with Semaglutide Once Weekly) trial stands as a landmark study in this field. This large, randomized, controlled trial investigated the effects of once-weekly semaglutide (1.0 mg) versus placebo in over 3,500 patients with T2D and CKD (defined by reduced eGFR and/or albuminuria). The trial was stopped prematurely in late 2023 due to clear evidence of efficacy based on an interim analysis, with full results emerging in 2024.
